Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Enzymotec Ltd (NASDAQ:ENZY)

7.90
Delayed Data
As of 10:25am ET
 +0.03 / +0.38%
Today’s Change
6.60
Today|||52-Week Range
10.70
-19.39%
Year-to-Date
Should You Get Rid of Enzymotec (ENZY) Now?
Aug 18 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close7.87
Today’s open7.69
Day’s range7.69 - 7.96
Volume500
Average volume (3 months)55,164
Market cap$179.2M
Dividend yield--
Data as of 10:25am ET, 08/25/2016

Growth & Valuation

Earnings growth (last year)-16.67%
Earnings growth (this year)-25.93%
Earnings growth (next 5 years)+24.61%
Revenue growth (last year)+6.98%
P/E ratio--
Price/Sales4.53
Price/Book1.31

Competitors

 Today’s
change
Today’s
% change
PTGXProtagonist Therapeu...-0.12-1.13%
EVGNEvogene Ltd-0.06-0.86%
PFNXPfenex Inc+0.09+1.16%
OSIROsiris Therapeutics ...+0.07+1.41%
Data as of 11:07am ET, 08/25/2016

Financials

Next reporting dateNovember 9, 2016
EPS forecast (this quarter)$0.07
Annual revenue (last year)$50.4M
Annual profit (last year)$6.7M
Net profit margin13.26%

Profile

Sector
Health Technology
Industry
Biotechnology
President &
Chief Executive Officer
Ariel Katz
Chief Financial Officer &
Vice President
Oren Bryan
Corporate headquarters
Migdal HaEmeq, Hazafon

Forecasts

Partner Offers

Search for Jobs